


Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**



**RECEIVED**

MAR 07 2002

TECH CENTER 1600/2900

Application No. 09/913,325

Applicant: Gleave et al

Filing Date: August 10, 2001

Title: TRPM-2 Antisense Therapy

Attorney Docket No.: UBC.P-020

Page 1 of 2

**U.S. PATENT DOCUMENTS**

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**FOREIGN PATENT DOCUMENTS**

	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	
TV	Buttayan et al., "Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death" <i>Molecular and Cellular Biology</i> Aug. 1989, Vol. 9, No. 8, pp. 3473-3481
	Millar et al., "Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?" <i>International Journal of Andrology</i> , 17:149-160
	Darby et al., "Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity" <i>Exp Nephrol</i> 1995; 3:234-239
	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays" <i>Nature Biotechnology</i> Volume 15, June 1997, pp. 537-541
	Sensibar et al., "Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin)," <i>Cancer Research</i> . June 1, 1995, Vol. 55, pp. 2431-2437
	Miyake et al., "Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer", <i>Cancer Research</i> 60, January 1, 2000, pp. 170-176
	Yang et al., "Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death", <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 97, Issue 11, pp 5907-5912, May 23, 2000
↓	Benner, et al., "Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies", <i>Journal of Pharmacological and Toxicological Method</i> , 37:229-235 (1997)

*Tracy Wilentz*

10/22/04



Substitute for form 1449

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

**RECEIVED**

**MAR 07 2002**

**TECH CENTER 1600/2900**

Application No. 09/913,325

Applicant: Gleave et al

Filing Date: August 10, 2001


Title: TRPM-2 Antisense Therapy

Attorney Docket No.: UBC.P-020

Page 2 of 2

TV	Kadomatsu, et al, "Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle", <i>Cancer Res</i> April 1, 1993, 53(7):1480-1483
I	Kyprianou, et al., "bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells.", <i>Int J Cancer</i> , Jan. 27, 1997, 70(3):341-348
I	Wright, et al., "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.", <i>Exp Cell Res</i> , Jan. 10, 1996, 222(1):54-60
↓	Bruchovsky, et al., "Control of tumor progression by maintenance of apoptosis.", <i>Prostate Suppl.</i> , 1996, 6:13-21

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

  
Examiner Signature

  
Date Considered



#9

Substitute for form 1449

RECEIVED

MAR 31 2003

TECH CENTER 1600/2300

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Application No.: 09/913,325  
Applicant: Gleave, et al.  
Filing Date: 08/10/2001  
Conf. No.: 8469  
Title: TRPM-2 Antisense Therapy  
Attorney Docket No.:  
UBC.P-020

Page 1 of 2

## U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
TV	5,789,389	Tarasewicz et al.	08/04/1998
TV	6,335,194 B1	Bennett et al.	01/01/2002

## FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
TV	WO 01/46455 A2	Yale University	06/28/2001

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
TV	Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; Vol. 61; March 1, 2001; 2183-2188.
	Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; Vol. 99, No. 7; April 2, 2002; 4656-4661.
	Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; Vol. 27, 2000; 81-100.
	Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; Vol. 99, No. 7; April 2, 2002; 4349-4354.
	Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; Vol. 81, No.4; April 2001; 453-463.
✓	Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; Vol. 42; 1998; S3-S21.

10/22/04



RECEIVED

MAR 31 2003

TECH CENTER 1600/2900

Substitute for form 1449

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Application No.: 09/913,325

Applicant: Gleave, et al.

Filing Date: 08/10/2001

Conf. No.: 8469

Title: TRPM-2 Antisense Therapy

Attorney Docket No.:

UBC.P-020

Page 2 of 2

TV	Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; Vol. 257; 2000; 101-110.
J	Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator; The Prostate Supplement; Vol. 9; 2000; 21-24.
✓	Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; <a href="http://www.genta.com">www.genta.com</a> ; 2001.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Signature

Date Considered


*D. J. Wilmore*

10/22/04




# Electronic Information Disclosure Statement

## TRPM-2 Antisense Therapy


Application:   
09/913325  
Confirmation: 8469  
Applicant(s): Martin Gleave  
Docket Number: UBC.P-020  
Group Art Unit: 1635  
Examiner: LaCourciere  
search string: (6383808).pn.

### US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
TV	P01	6383808	2002-05-07		Monia et al.	435	375

### Signature

Examiner Name	Date
	10/22/04



Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/913,325
Filing Date	8/10/2001
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Karen Lacourciere
Attorney Docket Number	UBC.P-020

Sheet	1	of	3
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>5</sup> (if known)				
TV ↓ ↓		WO 00/49937	8/31/2000	The University of British Columbia	Appear	
		WO 02/22635 A1	3/21/2002	ISIS Pharmaceuticals, Inc.		
		WO 03/062421 A1	7/31/2003	The University of British Columbia		
		WO 03/072591 A1	9/4/2003	University of British Columbia		

Examiner Signature	<i>[Signature]</i>	Date Considered	10/22/04
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Institute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

**Complete If Known**

Application Number	09/913,325
Filing Date	8/10/2001
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Karen Lacourciere
Attorney Docket Number	UBC-P-020

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
TV		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, 2001, Page(s) 39-49, Publisher: Elsevier Science Inc.	
		GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, Page(s) 79-92, Volume 21, Publisher: Kluwer Academic Publishers	
		GLEAVE ET AL., Targeting anti-apoptotic genes unregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen - and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Publisher: Kluwer Academic Publishers	
		GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, Page(s) 209-221, Volume 4	
		JONES ET AL., Molecules in focus Clusterin, The International Journal of Biochemistry and Cell Biology, 2002, Page(s) 427-431, Volume 34	
		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, Page(s) 337-349, Volume 8	
		MIYAKE ET AL., Synergistic Chemosensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model <sup>1</sup> , Clinical Cancer Research, 12/2001, Page(s) 4245-4251, Volume 7	
		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both <i>in Vitro</i> and <i>in Vivo</i> <sup>1</sup> , Clinical Cancer Research, 5/2000, Page(s) 1655-1663, Volume 6	
		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, International Journal of Biochemistry, 1995, Page(s) 633-645, Volume 27, Number 7, Publisher: Elsevier Science Ltd.	
		WILSON ET AL., Clusterin is a secreted mammalian chaperone, Frontlines, 3/2000, Page(s) 95-98	
		WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, Page(s) 917-925, Volume 227	

Examiner  
SignatureDate  
Considered

10/22/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

